Navigation Links
Letrozole Beats Tamoxifen in Breast Cancer Therapy

Novartis' Femara (letrozole), one of a new class of breast cancer drugs, worked better than standard therapy with tamoxifen in treating breast cancer in women// with advanced disease. Femara is a member of a new class of drugs called aromatase inhibitors, which work differently to prevent certain kinds of breast cancer than does tamoxifen.

This new drug, Letrozole shrank tumors better and helped more women survive. The US Food and Drug Administration (FDA) approved Femara as first-line hormonal treatment for advanced breast cancer in postmenopausal women. At that time, an FDA advisory panel enthusiastically backed Femara based on Novartis' research comparing the drug with a generic version of tamoxifen, the gold standard treatment for advanced breast cancer.

Femara was initially approved by the FDA in 1997 as treatment for advanced, hormonally sensitive breast cancer that had not responded to other treatments. Novartis believes Femara may also have potential early in the course of breast cancer and is studying the drug as a pre-surgical therapy.
'"/>




Page: 1

Related medicine news :

1. New Study Confers All Clear Status On Letrozole, Infertility Drug
2. Nasal Spray Beats Antihistamine
3. Identifying Irregular Heart Beats
4. Stomach Beats Can Tell the Truth About Lying
5. Radiation Overdose at the Beatson Oncology Centre
6. Radio Therapy To Cure Irregular Heart Beats
7. For Super-Obese Patients, Duodenal Switch Beats Gastric Bypass
8. Dawn Machine Beats Wintertime Blues
9. Hypertension Treatment: US Beats Europe
10. Low-dose Aspirin Beats High-dose After Cardiac Surgery
11. Tamoxifen does not adversely affect the brain
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at ... of the most popular and least understood books in the Holy Scriptures, Revelation. The ... that have baffled scholars for centuries. Many have tossed it off as mere rubbish, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... for healthcare compliance program management, will showcase a range of technology and learning ... Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 at ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) ... FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... Morris F. Collen, a pioneer in the field of medical informatics, this prestigious award ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... for the 49th Congress of the International Society of Paediatric Oncology (SIOP) ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... , Oct. 11, 2017  True Health, ... has amplified its effort during National Breast Cancer ... hereditary cancer risks. ... Clinical Oncology calculated that more than 10 million ... inherited mutations in BRCA1 or BRCA2 and have not ...
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/7/2017)... 6, 2017   Provista, a proven leader ... billion in purchasing power, today announced a new resource ... The Newsroom is the online home for case ... expert bios, news releases, slideshows and events. ... wealth of resources at their fingertips, viewers can also ...
Breaking Medicine Technology: